REGENXBIO Inc.
RGNX Healthcare Biotechnology
REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024. In the quarter to June 2026, revenue grew 405.7%, EPS grew 131.2% and free cash flow fell 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow RGNX
REGENXBIO Inc. (RGNX) Altman Z-score
REGENXBIO Inc.'s Altman Z-score for fiscal 2025 is −2.57, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −2.57 | 0.14 |
| FY2024 | −2.71 | (1.83) |
| FY2023 | −0.88 | (1.50) |
| FY2022 | 0.62 | (2.88) |
| FY2021 | 3.49 | 0.57 |
| FY2020 | 2.92 | (15.31) |
| FY2019 | 18.24 | (7.24) |
| FY2018 | 25.48 | (11.01) |
| FY2017 | 36.49 | 11.32 |
| FY2016 | 25.16 | 5.20 |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.36 | — | 0.43 | |
| Retained earnings / total assets | (2.49) | — | −3.48 | |
| EBIT / total assets | (0.36) | — | −1.17 | |
| Market value of equity / total liabilities | 2.12 | — | 1.27 | |
| Sales / total assets | 0.38 | — | 0.38 | |
| Altman Z-score | Distress zone | −2.57 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −7.82 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NGNE Neurogene Inc. compare | 8.7× |
| ENTX Entera Bio Ltd. compare | 6.2× |
| ALT Altimmune, Inc. compare | 0.2× |
| CBIO Crescent Biopharma, Inc. compare | −0.1× |
| ARVN Arvinas, Inc. compare | −0.6× |
| RGNX REGENXBIO Inc. | −2.6× |
| ALLO Allogene Therapeutics, Inc. compare | −3.7× |
| MNPR Monopar Therapeutics Inc. compare | — |
| YDES YD Bio Limited compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets